Sociedad Andaluza
de Patología Digestiva

Iniciar sesión

Tanto si ha olvidado su contraseña, como si se ha bloqueado por intentos erróneos de conexión deberá:

solicitar nueva contraseña

Buscar en la RAPD Online

Síguenos en las Redes Sociales




La nueva edición del Máster semipresencial de Enfermedad Inflamatoria Intestinal de la Universidad de Granada se in…

RAPD 2010
VOL 33
N4 Julio - Agosto 2010

Descargar número completo
Lázaro-Sáez, Bendezú-García, Carreño-González, Patrón-Román, and Casado-Martín: Hepatitis aguda tóxico-medicamentosa de evolución tórpida e infrecuente

Datos de la publicación

Hepatitis aguda tóxico-medicamentosa de evolución tórpida e infrecuente


We report the case of a 52 year old woman who presented, 12 days after initiating treatment with Captopril ®, a picture of asthenia and jaundice, with total bilirubin of 28.5 mg/dL, direct bilirubin of 27.4 mg/dL, GOT 933 U/L, GPT of 1486 U/L and a V factor of 18%. The cessation in the administration of the said drug was associated with a decrease in liver enzymes and in total bilirubin. But several days later, the level increased again to 37 mg/dL and a comprehensive etiological study showed positive AMA, so that the patient started a treatment with prednisone, with a suspected overlap syndrome without analytical improvement. However, a liver biopsy showed a cholestatic liver with normal portal tracts and no evidence of autoimmune hepatitis, so finally the diagnosis made was that of toxic hepatitis caused by Captopril ®. Acute injuries caused by this drug usually have cholestatic features, although hepatocellular and cholestatic injuries have also been reported, and sometimes a prolonged course has been described, including chronic liver damage with cholestatic or mixed pattern even when the drug ceased to be administered.